Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evogene Ltd.EVGN · Entity 8065 | Director | September 04, 2026 | September 30, 2026 |
| Odysight.ai Inc.ODYS · Entity 7081 | Director | February 10, 2025 | February 11, 2025 |
| PRECIGEN, INC.XON · Entity 4356 | Chief Business Officer | January 04, 2019 | January 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evogene Ltd.
Report date September 04, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-09-04 | Direct | 10,000 |
Reported balance
After 2026-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-04 · Grant · Acquired 10,000 · Balance 10,000 F1: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date. F2: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 10,000 Options. The Options were granted pursuant to, and are subject to the terms of, the Issuer's 2021 Share Incentive Plan. F3: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2030-04-20 | Direct | 5,625 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 5,625 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2032-09-15 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2033-05-11 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2034-06-15 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-08-18 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 10,000 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.
F2: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 10,000 Options. The Options were granted pursuant to, and are subject to the terms of, the Issuer's 2021 Share Incentive Plan.
F3: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.
F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Odysight.ai Inc.
Report date February 10, 2025 · Filed February 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2030-09-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-02-10 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The options vest and become exercisable over three years, with 1/3 vesting on August 13, 2024 with the remaining 2/3 vesting in equal quarterly installments over the following two years, subject to the Reporting Person's continued service. |
| Options to purchase common stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2031-09-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-02-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The options vest and become exercisable over three years, with 1/3 vesting on September 16, 2025 with the remaining 2/3 vesting in equal quarterly installments over the following two years, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable over three years, with 1/3 vesting on August 13, 2024 with the remaining 2/3 vesting in equal quarterly installments over the following two years, subject to the Reporting Person's continued service.
F2: The options vest and become exercisable over three years, with 1/3 vesting on September 16, 2025 with the remaining 2/3 vesting in equal quarterly installments over the following two years, subject to the Reporting Person's continued service.
PRECIGEN, INC.
Report date January 04, 2019 · Filed January 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,482 |
Reported balance
After 2019-01-04 transaction · row 1
1 source rowRow 1 · 2019-01-04 · Grant · Acquired 13,774 · Balance 19,482 F1: These shares of common stock resulted from the grant and immediate vesting of restricted stock units that were issued as a portion of the reporting person's 2018 incentive compensation. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 75,758 |
Reported balance
After 2019-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-04 · Grant · Acquired 75,758 · Balance 75,758 F2: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3: The restricted stock units vest in four equal annual installments beginning January 4, 2020. |
| Common StockSEC Table I · non-derivative | IndirectBy The Nimrodi Family Trust | 7,369 |
Reported balance
Holding disclosure · report date 2019-01-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 7,369 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock resulted from the grant and immediate vesting of restricted stock units that were issued as a portion of the reporting person's 2018 incentive compensation.
F2: Each restricted stock unit represents a contingent right to receive one share of XON common stock.
F3: The restricted stock units vest in four equal annual installments beginning January 4, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 30, 2026 08:09 UTC | Evogene Ltd. EVGN · Entity 8065 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001178913-26-004662 · ownership.xml · derivative · entry 1 Nimrodi Nir · CIK 0001602806 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2036-09-04 F1 · derivative.exercise_price: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date. F2 · kind: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 10,000 Options. The Options were granted pursuant to, and are subject to the terms of, the Issuer's 2021 Share Incentive Plan. F3 · derivative.exercise_date: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 01:07 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 75,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000129 · edgar.xml · derivative · entry 3 Nimrodi Nir · CIK 0001602806 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,758 Underlying: Common Stock · 75,758 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 4, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 4, 2020. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 01:07 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantCommon Stock | 13,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000129 · edgar.xml · nonDerivative · entry 1 Nimrodi Nir · CIK 0001602806 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,482 F1 · price: These shares of common stock resulted from the grant and immediate vesting of restricted stock units that were issued as a portion of the reporting person's 2018 incentive compensation. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 23:45 UTC | PRECIGEN, INC. XON · Entity 4356 | SaleCommon Stock | 4,058 | $7.07 | $28,692.09 |
DisclosureSEC source: 0001123292-19-000080 · edgar.xml · nonDerivative · entry 2 Nimrodi Nir · CIK 0001602806 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,708 F2 · kind: This sale was effected pursuant to the terms of a 10b5-1 plan adopted by the reporting person and was made in order to pay the tax liability arising from the vesting of restricted stock units. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:45 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionRestricted Stock Units · Derivative | 9,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-19-000080 · edgar.xml · derivative · entry 4 Nimrodi Nir · CIK 0001602806 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,297 Underlying: Common Stock · 9,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in three equal annual installments on each of January 2, 2020, 2021 and 2022. F3 · derivative.expiration_date: The restricted stock units were granted on January 2, 2018, and the remaining restricted stock units vest in three equal annual installments on each of January 2, 2020, 2021 and 2022. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:45 UTC | PRECIGEN, INC. XON · Entity 4356 | Exercise / conversionCommon Stock | 9,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000080 · edgar.xml · nonDerivative · entry 1 Nimrodi Nir · CIK 0001602806 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,766 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document |
| January 02, 2018 Filed Jan 9, 2018 01:20 UTC | PRECIGEN, INC. XON · Entity 4356 | GrantRestricted Stock Units · Derivative | 39,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001123292-18-000102 · edgar.xml · derivative · entry 1 Nimrodi Nir · CIK 0001602806 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,063 Underlying: Common Stock · 39,063 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 2, 2019. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 2, 2019. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 12:33 UTC | PRECIGEN, INC. XON · Entity 4356 | PurchaseCommon Stock | 3,369 | $18.75 | $63,168.75 |
DisclosureSEC source: 0001225385-17-000098 · edgar.xml · nonDerivative · entry 1 Nimrodi Nir · CIK 0001602806 · SVP-Corporate Development 10b5-1 filing: Not disclosed Ownership: Indirect · By The Nimrodi Family Trust Disclosed balance after: 7,369 F1 · price: The price reported in Column 4 is a weighted average price of shares purchased in multiple transactions. The reporting person undertakes to provide to Intrexon Corporation ("Intrexon"), any security holder of Intrexon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.